8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

The Protective Effects of EMF-LTE against DNA Double-Strand Break Damage In Vitro and In Vivo

Bioeffects Seen

Jin H, Kim K, Park GY, Kim M, Lee H-J, Jeon S, Kim JH, Kim HR, Lim KM, Lee YS · 2021

Share:

EMF-LTE exposure demonstrated protective effects against DNA double-strand break damage in both cultured skin cells and mouse skin tissue in vivo.

Plain English Summary

Summary written for general audiences

This study examined whether long-term evolution (LTE) radiofrequency electromagnetic field (EMF) exposure affects DNA damage in skin cells and mouse models. The researchers found that EMF-LTE exposure alone did not cause DNA damage, but notably reduced DNA double-strand break damage induced by ionizing radiation and bleomycin, suggesting a protective effect mediated partly through p53 upregulation.

Why This Matters

This finding contrasts with concerns about potential genotoxic effects of radiofrequency EMF exposure and aligns with earlier observations that other EMF types can enhance DNA repair mechanisms. The authors appropriately note that further research is needed to establish relevance to human health outcomes.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Jin H, Kim K, Park GY, Kim M, Lee H-J, Jeon S, Kim JH, Kim HR, Lim KM, Lee YS (2021). The Protective Effects of EMF-LTE against DNA Double-Strand Break Damage In Vitro and In Vivo.
Show BibTeX
@article{jin_h_kim_k_park_gy_kim_m_lee_h_j_jeon_s_kim_jh_kim_hr_lim_km_lee_ys_ce2840,
  author = {Jin H and Kim K and Park GY and Kim M and Lee H-J and Jeon S and Kim JH and Kim HR and Lim KM and Lee YS},
  title = {The Protective Effects of EMF-LTE against DNA Double-Strand Break Damage In Vitro and In Vivo},
  year = {2021},
  doi = {10.1093/eurheartj/ehab094},
  
}
DOI: 10.1093/eurheartj/ehab094PubMed: 34066270

Quick Questions About This Study

Yes, the DAPA-CKD trial found dapagliflozin reduced all-cause mortality by 31% in chronic kidney disease patients over 2.4 years of treatment, with particularly strong effects on preventing non-cardiovascular deaths.
In this study, 41.3% of deaths were from non-cardiovascular causes (primarily infections and malignancies), 36.8% from cardiovascular causes, and 21.9% had undetermined causes among the 247 patients who died.
The DAPA-CKD trial included 4,304 participants with chronic kidney disease, randomly assigned to receive either dapagliflozin 10 mg daily (2,152 patients) or placebo (2,152 patients) for median follow-up of 2.4 years.
Eligible patients had estimated glomerular filtration rate (eGFR) between 25-75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio (UACR) of 200-5000 mg/g, indicating moderate to severe chronic kidney disease with protein in urine.
Yes, the 31% reduction in all-cause mortality with dapagliflozin was consistent across all pre-specified subgroups analyzed in the study, suggesting the survival benefit applies broadly to chronic kidney disease patients.